Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06522737 2026-02-11

TERZO

Phase 3 Recruiting

124 enrolled

Phase 1 Active not recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT05044039 2026-02-02

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

42 enrolled

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03961672 2026-01-05

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

15 enrolled 13 charts

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04331119 2025-12-30

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

17 enrolled

Phase 2 Not yet recruiting

Lymphoma, T-Cell

NCT07293403 2025-12-19

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

25 enrolled

Lymphoma, T-Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

LymphoidOther hematologic neoplasmPlasma cell

14 enrolled

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT05010005 2025-12-03

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Phase 1 Recruiting

70 enrolled

Phase 1/2 Active not recruiting

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT03534323 2025-08-14

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

67 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07001384 2025-08-14

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

30 enrolled

Phase 1 Active not recruiting

Lymphoma, Large-Cell, Anaplastic

NCT02783625 2025-06-03

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

114 enrolled

Phase EARLY_PHASE1 Completed

Lymphoma, Lymphoma, T-Cell

NCT04890236 2025-01-20

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

4 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03892044 2024-05-02

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

7 enrolled

13 enrolled 10 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02204982 2023-09-28

DYNAMO + R

Phase 3 Terminated

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02391545 2023-09-28

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Phase 1/2 Terminated

55 enrolled 13 charts

319 enrolled 18 charts 1 FDA

Lymphoma, Follicular

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Phase 3 Completed

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02049515 2023-09-21

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Phase 3 Completed

99 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05976997 2023-08-04

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Phase 2 Unknown

36 enrolled

Lymphoma, T-Cell, Peripheral

NCT03370185 2023-02-28

BRIO

Phase 2 Withdrawn

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Phase 1 Terminated

3 enrolled

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Phase 1 Withdrawn

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT04836832 2022-06-07

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04209621 2022-03-09

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Terminated

3 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02576275 2021-03-17

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Phase 3 Withdrawn

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02605694 2021-03-17

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Phase 2 Withdrawn

Lymphoma

NCT04342117 2021-03-17

REAL

Terminated

2 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04707079 2021-01-13

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Phase 2 Unknown

24 enrolled

Lymphoma, Follicular

NCT02598570 2017-02-06

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

7 enrolled

Lymphoma, Hereditary Sensory and Autonomic Neuropathies

NCT02640833 2016-07-26

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Phase 1 Withdrawn

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

48 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT02028039 2014-01-06

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 2 Withdrawn